Kristie L. Kahl

The phase 3 ASCENT trial designed to evaluate sacituzumab govitecan-hziy in patients with brain metastasis-negative, metastatic triple-negative breast cancer met its primary end point of progression-free survival.

The FDA lifted the partial clinical hold on the on the pivotal phase 2 trial of camidanlumab tesirine (Cami) – designed to evaluate the antibody drug conjugate in patients with relapsed or refractory Hodgkin lymphoma.

Adjuvant immunotherapy induced improved survival compared with those who did not in patients with stage 3 melanoma, according to data from a large real-world database.

RO7198457 in combination with atezolizumab induced significant levels of neoantigen-specific immune responses with a manageable safety profile in patients with locally advanced or metastatic solid tumors.

Andrea Dwyer addressed why it is important to raise global awareness around the increasing rate of EAO-CRC, and how healthcare providers can get involved.

An investigational PD-L1 PROBODY therapeutic, CX-072, demonstrated durable responses and appeared tolerable in patients across multiple tumor types.

The phase 3 PROTECTIVE-2 (Study 106) trial met its primary and secondary end points in preventing chemotherapy-induced neutropenia following treatment with plinabulin in combination with pegfilgrastim.

The FDA approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome.

Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.

Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression.

The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.

The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC.

Treatment with olaparib in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.

Researchers showed that integration of a comprehensive geriatric assessment with geriatrician-led management care improved quality of life for older adults with cancer.

The FDA approved the first therapy to treat cancers with rearranged during transfection (RET) gene alterations.

The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications.

The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with BRAFV600E-positive metastatic colorectal cancer.

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

The FDA approved the combination use of nivolumab plus ipilimumab for the treatment of patients with HCC who have been previously treated with sorafenib.

At the 37th Annual Miami Breast Cancer Conference, Valerie Lemaine, MD, MPH, FRCSC, told physicians what they need should know and discuss with their patients about BIA-ALCL.

A study, published in Nature Cancer, demonstrates the quick and evolving revolutions of resistance mechanisms in small cell lung cancer.

The FDA granted a priority review to the new drug application for lurbinectedin as a treatment for patients with small cell lung cancer.

The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC.

A study of the Veterans Affairs health system found that, despite trends suggesting otherwise, African American men with prostate cancer had similar survival outcomes, compared with non-Hispanic white men.

Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.

The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.

The FDA granted priority review to rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.

The FDA approved enfortumab vedotin-ejfv (Padcev)-the first drug to treat adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.